Taylor Hodges
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 82.1% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $28,372, more than ten times the $203 reported in 2022. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $119.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$27K
- Amgen$873
- E.r. Squibb & Sons, L.L.C.$576
- AstraZeneca$570
- Pfizer$563
- Boehringer Ingelheim$519
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$19,06358%
- Travel & lodging$6,11519%
- Food & beverage$7,37823%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $26,812 |
| Amgen | 26 | $873 |
| E.r. Squibb & Sons, L.L.C. | 14 | $576 |
| AstraZeneca | 25 | $570 |
| Pfizer | 25 | $563 |
| Boehringer Ingelheim | 31 | $519 |
| Heartflow, Inc. | 13 | $473 |
| Novartis | 17 | $386 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $296 |
| Bayer | 10 | $273 |
| Medtronic | 8 | $268 |
| Scpharmaceuticals Inc. | 8 | $167 |
| Esperion Therapeutics, Inc. | 8 | $145 |
| Johnson & Johnson | 7 | $141 |
| Lilly USA, LLC | 6 | $121 |
| Lexicon Pharmaceuticals, Inc. | 3 | $89 |
| Abiomed | 1 | $76 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| Boston Scientific | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| GSK | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $35 |
| Bridgebio Pharma, Inc. | 2 | $29 |
| Medicomp Inc | 1 | $28 |
| Terumo Medical Corporation | 1 | $21 |
| Merck | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,657 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $311,176 |
| Repatha SureclickEvolocumab | 112 | $159,577 |
| EntrestoSacubitril/Valsartan | 53 | $96,835 |
| JardianceEmpagliflozin | 73 | $91,354 |
| FarxigaDapagliflozin Propanediol | 56 | $65,714 |
| XareltoRivaroxaban | 35 | $48,808 |
| Praluent PenAlirocumab | 38 | $42,648 |
| WegovySemaglutide | 15 | $27,281 |
| Ranolazine ErRanolazine | 137 | $15,882 |
| OzempicSemaglutide | 12 | $14,929 |
| Metoprolol Succinate | 487 | $8,225 |
| Nebivolol Hcl | 93 | $6,724 |
| Rosuvastatin Calcium | 361 | $6,353 |
| Atorvastatin Calcium | 294 | $4,565 |
| Prasugrel Hcl | 52 | $4,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $563 | $311,176216 claims |
| NovartisEntresto | $386 | $96,83553 claims |
| Boehringer IngelheimJardiance | $519 | $91,35473 claims |
| AstraZenecaFarxiga | $570 | $65,71456 claims |
| Johnson & JohnsonXarelto | $141 | $48,80835 claims |
| Novo NordiskWegovy, Ozempic | $26,812 | $42,21127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.
Other family in Lewes
- Caryn ChasanovLewes$12K
- Alice HoppleLewes$11K
- Sarah RobinsonLewes$8K
- Nina VarugheseLewes$8K
- Ashley HillLewes$6K
- Helen MerrickLewes$5K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.